Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-
phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

Primary myelofibrosis (PMF) is one of three myeloproliferative neoplasms (MPN) that are
morphologically and molecularly inter-related, the other two being polycythemia vera (PV) …

Transformation from chronic (CP) to blast phase (BP) in myeloproliferative neoplasm (MPN)
remains poorly characterized, and no specific mutation pattern has been highlighted. BP …

Accelerated-phase myelofibrosis, currently defined by circulating blasts 10% to 19%, usually
confers very high risk for progression and poor outcome. The outcome of hematopoietic …

Simple Summary The development of BCL-2 inhibitors as a pivotal approach in cancer
treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a …

Small molecule inhibitors targeting JAK2 provide symptomatic benefits for myeloproliferative
neoplasm (MPN) patients and are among first‐line therapeutic agents. However, despite all …

Abstract Disease Overview Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
(MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not …